%0 Journal Article
%A Ng, Alexander B C D
%A Asif, Aqua
%A Agarwal, Ridhi
%A Panebianco, Valeria
%A Girometti, Rossano
%A Ghai, Sangeet
%A Gómez-Gómez, Enrique
%A Budäus, Lars
%A Barrett, Tristan
%A Radtke, Jan Philipp
%A Kesch, Claudia
%A De Cobelli, Francesco
%A Pham, Tho
%A Taneja, Samir S
%A Hu, Jim C
%A Tewari, Ash
%A Rodríguez Cabello, Miguel Á
%A Dias, Adriano B
%A Mynderse, Lance A
%A Borghi, Marcelo
%A Boesen, Lars
%A Singh, Paras
%A Renard-Penna, Raphaële
%A Leow, Jeffrey J
%A Falkenbach, Fabian
%A Pecoraro, Martina
%A Giannarini, Gianluca
%A Perlis, Nathan
%A López-Ruiz, Daniel
%A Kastner, Christof
%A Schimmöller, Lars
%A Rossiter, Marimo
%A Nathan, Arjun
%A Khetrapal, Pramit
%A Chan, Vinson Wai-Shun
%A Haider, Aiman
%A Clarke, Caroline S
%A Punwani, Shonit
%A Brew-Graves, Chris
%A Dickinson, Louise
%A Mitra, Anita
%A Brembilla, Giorgio
%A Margolis, Daniel J A
%A Takwoingi, Yemisi
%A Emberton, Mark
%A Allen, Clare
%A Giganti, Francesco
%A Moore, Caroline M
%A Kasivisvanathan, Veeru
%T Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial.
%J The journal of the American Medical Association
%V nn
%@ 0254-9077
%C Chicago, Ill.
%I American Medical Association
%M DKFZ-2025-01888
%P nn
%D 2025
%Z epub
%X Multiparametric magnetic resonance imaging (MRI), with or without prostate biopsy, has become the standard of care for diagnosing clinically significant prostate cancer. Resource capacity limits widespread adoption. Biparametric MRI, which omits the gadolinium contrast sequence, is a shorter and cheaper alternative offering time-saving capacity gains for health systems globally.To assess whether biparametric MRI is noninferior to multiparametric MRI for diagnosis of clinically significant prostate cancer.A prospective, multicenter, within-patient, noninferiority trial of biopsy-naive men from 22 centers (12 countries) with clinical suspicion of prostate cancer (elevated prostate-specific antigen [PSA] level and/or abnormal digital rectal examination findings) from April 2022 to September 2023, with the last follow-up conducted on December 3, 2024.Participants underwent multiparametric MRI, comprising T2-weighted, diffusion-weighted, and dynamic contrast-enhanced (DCE) sequences. Radiologists reported abbreviated biparametric MRI first (T2-weighted and diffusion-weighted), blinded to the DCE sequence. After unblinding, radiologists reported the full multiparametric MRI. Patients underwent a targeted biopsy with or without systematic biopsy if either biparametric MRI or multiparametric MRI was suggestive of clinically significant prostate cancer.The primary outcome was the proportion of men with clinically significant prostate cancer. Secondary outcomes included the proportion of men with clinically insignificant cancer. The noninferiority margin was 5
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40928788
%R 10.1001/jama.2025.13722
%U https://inrepo02.dkfz.de/record/304499